NTRA Natera Inc
Company Analysis
Latest News
🔴 Natera is trading 4.6% down today amid broader risk-off trading
Natera is trading 4.55% lower at $394.56 as of 11:29 a.m. ET on October 22, 2026, with broader risk-off trading the likeliest context; no clear...
🔴 Natera is trading 19.04% down in after-hours trading
Natera is trading 19.04% down at $318.53 after-hours, with no verified late-breaking company announcement explaining the drop. - It closed the October 16...
🔴 Natera is trading 5% down today as biotech lags broader indexes
Natera is trading at $404.91, down 4.87%, amid biotech-sector pressure; no specific catalyst directly explaining the decline was found. - The sector ETF fell...
Natera Launches Major Breast Cancer Trial to Guide Treatment Decisions
Natera launched a Phase III clinical trial. It partners with Alliance Foundation Trials (AFT) and Genentech. The trial evaluates a new approach for...
🟢 Natera is trading 5.3% up in pre-market
Natera is trading 5.27% higher at $430.00, with no fresh company-specific catalyst confirmed for October 2, 2026. - The previously reported Japan regulatory...
🟢 Natera is trading 5.5% up in pre-market; no fresh catalyst confirmed
Natera is trading 5.51% up in pre-market at $436.10 on October 1, versus its September 30 close of $413.31, with no clearly confirmed fresh catalyst. - The...
🟢 Natera is trading 5% up in pre-market after Japan approved Signatera for muscle-invasive bladder cancer
Natera is trading 5.03% higher at $429.34 as investors respond to Japan’s September 22 approval of Signatera as a companion diagnostic for muscle-invasive...
🟢 Natera is trading 4.3% up today on Japan's Signatera companion-diagnostic approval
Natera is trading 4.3% up at $407.55 as investors focus on Signatera’s regulatory and clinical progress. - Japan approved Signatera as a companion diagnostic...
🔴 Natera is trading 13.65% down in after-hours trading as Nasdaq and S&P 500 fall
Natera is trading 13.65% lower at $337.46 in after-hours trading, with the decline appearing primarily tied to risk-off market conditions. - Shares closed at...
🟢 Natera rises 4.1% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
Natera Signatera predicts lung cancer recurrence, citing largest-ever MRD study results
Natera presented new data for its Signatera molecular residual disease (MRD) test at the IASLC 2026 World Conference on Lung Cancer. The study analyzed over...
Natera Chairman Sells $35M in Stock Following 97% Annual Rally
Natera Executive Chairman Matthew Rabinowitz sold 101,000 shares of company stock on September 14 and 15. The total value of the transactions reached...
🟢 Natera rises 4.0% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Natera is trading 4.14% up today
Natera is trading at $342.54, up +4.14% on September 14, 2026, outperforming the broader market as major indexes are lower. - Management presented growth...
Natera initiated at Buy with $435 target, citing MRD market leadership
UBS initiated coverage on Natera with a Buy rating. The bank established a price target of $435 for the stock. Analysts identified Natera as a leader in the...
🟢 Natera is trading 4.5% up in pre-market; no confirmed company-specific catalyst identified
Natera is trading 4.52% up at $343.00, with no confirmed company-specific announcement identified for September 8, 2026. - The latest notable company news was...
Natera Validates Signatera for Lymphoma, Outperforming Standard PET/CT Scans
Natera published data in the journal Blood Neoplasia validating its Signatera molecular residual disease (MRD) test for lymphoma. The study evaluated 144...
Viking Global Takes New $106M Position in Diagnostics Firm Natera
Andreas Halvorsen's Viking Global Investors initiated a significant new stake in Natera Inc., a genetic testing and diagnostics company. The investment, valued...
Farallon Capital Opens Major New $641M Position in Natera (NTRA)
In a recent disclosure, Farallon Capital Management reported establishing a significant new stake in Natera, Inc. (NTRA), a leader in cell-free DNA (cfDNA)...
🟢 Natera is trading 4.78% up in pre-market with no clear company-specific catalyst identified
Natera is trading 4.78% up at $343.40, with no clear August 25, 2026 company-specific catalyst identified. - Latest major company news was August 6, 2026...